The study is a randomized placebo controlled trial to determine whether repeated postoperative prophylactic ondansetron ("Zofran") administration will prevent postoperative and/or postdischarge nausea and vomiting in patients undergoing ambulatory hip arthroscopy. Ondansetron will be administered in the intra- and post-operative period. These individuals will be followed on postoperative days 1, 2, and 3. It is hypothesized that the incidence of postdischarge nausea and vomiting (PDNV) will be significantly decreased by postoperative prophylactic administration of multiple doses of ondansetron (Zofran).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
98
The study group will receive 4 mg of IV ondansetron perioperatively and also postoperative oral ondansetron tablets (8 mg each day for two days). The tablets will be concealed in generic capsules prepared by the pharmacy at the Hospital for Special Surgery to make the ondansetron tablets indistinguishable from the placebos.
The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days). These placebo tablets will contain lactose and be indistinguishable from the study medication.
Hospital for Special Surgery
New York, New York, United States
Incidence of Nausea
Percentage of participants with nausea
Time frame: Postdischarge Day 1
Severity of Nausea
Percentage of participants reporting moderate or severe nausea in the first 24 hours
Time frame: Postdischarge Day 1
Impact of Nausea and Vomiting on Quality of Life
Percentage of participants whose quality of life was impacted by nausea and vomiting
Time frame: Postdischarge Day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.